Login / Signup

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.

Thomas Van StappenNiels Vande CasteeleGert Van AsscheMarc FerranteSéverine VermeireAnn Gils
Published in: Gut (2017)
2011-002061-38; Post-results.
Keyphrases
  • phase iii
  • study protocol
  • high throughput
  • phase ii
  • clinical trial
  • ulcerative colitis
  • adverse drug
  • open label
  • drug induced
  • electronic health record